Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

 Move your mouse over me

PRN News
Special Announcement

Welcome to our newly renovated web site! Take a moment to browse:

  • New articles in our peer reviewed online journal, The PRN Notebook
  • Continuing Medical Education credit for selected articles from The PRN Notebook
  • Access to past articles, with improved navigation and content search capabilities
  • Expanded membership to PRN including advance notice and online registration to attend our monthly meetings in New York City
  • New, downloadable images, including our new, interactive HIV life-cycle
Featured ArticlesVisit The PRN Notebook
image

management
Teresa H. Evering, MD and Martin Markowitz, MD

HIV-1 Integrase Inhibitors

The integrase inhibitors are a welcome addition to the treatment armamentarium for HIV/AIDS in treatment-experienced patients failing available antiretroviral regimens. The promising efficacy and tolerability profile of the integrase inhibitors, absence of cross-resistance with other antiretroviral classes, and demonstrated synergism of the integrase inhibitors in combination with approved antiretroviral agents place them in a position to become important components of effective combination antiretroviral regimens in individuals living with HIV/AIDS.

Full text:   >HTML | >PDF | >CME
image

complications
Todd T. Brown, MD, PhD

Selected Endocrine Topics in HIV: Osteoporosis and Adrenal Insufficiency

The care of HIV-infected patients has become increasingly complex. Endocrine problems, such as osteoporosis and AI, have been frequently reported in the HAART era. Additional considerations may be required regarding the etiologies, diagnosis, and treatment compared with the general population. Further research is required to understand the intricacies of these problems in HIV-infected patients in order to provide optimal care.

Full text:   >HTML | >PDF | >CME
image

management
Athe Tsibris, MD

Update On CCR5 Inhibitors: Scientific Rationale, Clinical Evidence, and Anticipated Uses

The CCR5 antagonists are a welcome addition to the therapeutic armamentarium available for antiretroviral-experienced patients. Currently, their use in antiretroviral-naive patients should be restricted to enrollment in ongoing or planned clinical trials. The CCR5 antagonist maraviroc is FDA-approved for treatment-experienced patients with R5 virus (only), and no patient should receive maraviroc without first undergoing a tropism assay.

Full text:   >HTML | >PDF | >CME
image

progression
Saurabh Mehandru, MD

The Gastrointestinal Tract in HIV-1 Infection: Questions, Answers, and More Questions!

The GI tract is targeted during all stages of HIV disease, and this is especially so during acute and early HIV infection. CD4 cells are preferentially lost from the GI tract within weeks of HIV infection. Despite long-term antiretroviral therapy, CD4+T-cell reconstitution remains deficient in the GI tract in spite of the reconstitution seen in the peripheral blood.

Full text:   >HTML | >PDF | >CME
More PRN News Capsules...

Provider Resources

CME

Members Only

PRN is pleased to offer this new CME opportunity designed for physicians, nurse practitioners and physician assistants caring for patients with or at risk for HIV disease and its many complications. Based on content from The PRN Notebook, credit for each course will be available for a limited period of time noted on each activity.

View CME

Membership is now open to our national subscribers. To apply you must be a licensed physician, nurse practitioner or physician assistant, who provides care to patients with or at risk for HIV/AIDS.

Coming Soon

PRN Online is made possible through Sustaining Educational grants from the following:

PRN Online is also made possible through substantial educational grants from the following: